A carregar...
Toward a Single-Dose Cure for Buruli Ulcer
A single dose of Q203 (Telacebec), a phase 2 clinical candidate for tuberculosis, eradicates Mycobacterium ulcerans in a mouse model of Buruli ulcer infection without relapse up to 19 weeks posttreatment. Clinical use of Q203 may dramatically simplify the clinical management of Buruli ulcer, a negle...
Na minha lista:
| Publicado no: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society for Microbiology
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7449209/ https://ncbi.nlm.nih.gov/pubmed/32631818 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00727-20 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|